About this document

Fmed 11 1464610 by Watsonn Rayglann is a document available to read on EtoBox.

This research investigates the mechanisms of acquired resistance to regorafenib in hepatocellular carcinoma (HCC), focusing on the role of EGFR bypass activation. The study found that EGFR overexpression in resistant HCC cells promotes resistance through RAS/RAF/ERK signaling, and that inhibiting EGFR with gefitinib can restore sensitivity to regorafenib. These findings suggest that combining gefitinib with regorafenib may be an effective treatment strategy for advanced HCC patients experiencing resistance

Author

Watsonn Rayglann

Language

EN